Case 3:18-cv-00347-CAB-MDD Document 301-4 Filed 01/15/21 PageID.27257 Page 1 of 13
`
`
`
`
`
`EXHIBIT K
`
`TO TANNER DECLARATION
`
`

`

`Case 3:18-cv-00347-CAB-MDD Document 301-4 Filed 01/15/21 PageID.27258 Page 2 of 13
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`25
`
`26
`
`27
`
`28
`
`
`
`
`
`
`
`WILSON SONSINI GOODRICH & ROSATI P.C.
`PAUL D. TRIPODI II (SBN 162380)
`ptripodi@wsgr.com
`GRACE J. PAK (SBN 277705)
`gpak@wsgr.com
`633 West Fifth Street, Suite 1550
`Los Angeles, CA 90071
`Telephone: 323-210-2900
`Fax: 866-974-7329
`
`WENDY L. DEVINE (SBN 246337)
`wdevine@wsgr.com
`One Market Plaza
`Spear Tower, Suite 3300
`San Francisco, California 94105-1126
`Telephone: 415-947-2000
`Fax: 415-947-2099
`
`NATALIE J. MORGAN (SBN 211143)
`nmorgan@wsgr.com
`CHRISTINA DASHE (SBN 292360)
`cdashe@wsgr.com
`12235 El Camino Real
`San Diego, CA 92130
`Telephone: 858-350-2300
`Fax: 858-350-2399
`
`SARA L. TOLBERT (SBN 300945)
`stolbert@wsgr.com
`650 Page Mill Road
`Palo Alto, CA 94304
`Telephone: 650-593-9300
`Fax: 650-493-6811
`
`Attorneys for Plaintiff NuVasive, Inc.
`
`UNITED STATES DISTRICT COURT
`
`SOUTHERN DISTRICT OF CALIFORNIA – SAN DIEGO DIVISION
`
`NUVASIVE, INC., a Delaware
`corporation,
`
` Plaintiff,
`
`v.
`
`
`
`ALPHATEC HOLDINGS, INC., a
`Delaware corporation, and ALPHATEC
`SPINE, INC., a California corporation,
`
` Defendants.
`
`)
`)
`)
`)
`)
`)
`)
`)
`)
`)
`)
`)
`)
`
`Case No. 18-cv-00347-MDD-CAB
`
`PLAINTIFF NUVASIVE,
`INC.’S SUPPLEMENTAL
`OBJECTIONS AND
`RESPONSES TO
`DEFENDANTS’ FIRST SET OF
`INTERROGATORIES (NOS. 1-
`4, 8, 10, 11)
`
`
`
`
`
`
`NUVASIVE’S SUPPL OBJ.
`& RESPONSES TO DEFS’
`1ST SET OF ROGS
`
`
`
`18-cv-00347-CAB-MDD
`
`
`
`EXHIBIT K
`PAGE 5
`
`

`

`Case 3:18-cv-00347-CAB-MDD Document 301-4 Filed 01/15/21 PageID.27259 Page 3 of 13
`
`
`
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
` DHF-06-008 (re shims and XLIF kit components):
`
`NUVA_ATEC0011053 – NUVA_ATEC0012429,
`
`NUVA_ATEC0012466 – NUVA_ATEC0012541,
`
`NUVA_ATEC0012598 – NUVA_ATEC0012617,
`
`NUVA_ATEC0012621 – NUVA_ATEC0012839,
`
`NUVA_ATEC0012936 – NUVA_ATEC0012952;
`
` DHF-06-018 (re dilators): NUVA_ATEC0014000 –
`
`NUVA_ATEC0014446;
`
` DHF-08-012 (re shims and XLIF kit components):
`
`NUVA_ATEC13829 – NUVA_ATEC0013999;
`
` DHF-09-020 (re access system): NUVA_ATEC0012953 –
`
`NUVA_ATEC0013828;
`
` DHF-14-020 (re dilators): NUVA_ATEC0012927 –
`
`NUVA_ATEC0012935.
`
`Discovery is ongoing and NuVasive reserves its right to amend or
`
`supplement its response to this interrogatory.
`
`17
`
`INTERROGATORY NO. 3:
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`25
`
`For each asserted claim of the patents-in-suit, describe in detail the facts
`
`and circumstances relating to the first written description, offer for sale, sale,
`
`public disclosure, public use, or disclosure to any person other than a named
`
`inventor of the claimed invention, including, without limitation, the identities of
`
`the persons involved in each such event, the identities of the persons most
`
`knowledgeable regarding each such event, the date on which each such event
`
`occurred, and the identification of each document that reflects or relates to such
`
`facts and circumstances.
`
`26
`
`RESPONSE TO INTERROGATORY NO. 3:
`
`27
`
`28
`
`
`
`
`
`NUVASIVE’S SUPPL OBJ.
`& RESPONSES TO DEFS’
`1ST SET OF ROGS
`
`20
`
`18-cv-00347-CAB-MDD
`
`EXHIBIT K
`PAGE 6
`
`

`

`Case 3:18-cv-00347-CAB-MDD Document 301-4 Filed 01/15/21 PageID.27260 Page 4 of 13
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`25
`
`26
`
`27
`
`28
`
`
`
`
`
`
`NuVasive incorporates by reference each of the General Objections.
`
`NuVasive objects to this interrogatory on the grounds that it contains at least three
`
`discrete subparts, is compound, and constitutes at least three interrogatories.
`
`NuVasive objects to this interrogatory as vague and ambiguous with respect to the
`
`term “the circumstances.” NuVasive objects to this interrogatory on the grounds
`
`and to the extent it is overly broad, unduly burdensome, not proportional to the
`
`needs of the case, and not relevant to any claim or defense in this case.
`
`Specifically, NuVasive objects to the interrogatory to the extent it calls for
`
`NuVasive to “describe in detail” the circumstances relating to the first descriptions,
`
`disclosures and sales of the claimed inventions. NuVasive objects to this
`
`interrogatory to the extent it seeks “Privileged Information.” NuVasive objects to
`
`this interrogatory to the extent it calls for legal conclusions. NuVasive objects to this
`
`interrogatory to the extent it attempts the shift the burden of proof regarding
`
`invalidity to NuVasive. NuVasive objects to this interrogatory to the extent it seeks
`
`information no longer in NuVasive’s possession, custody, or control.
`
`Subject to and without waiving the foregoing objections, NuVasive
`
`responds as follows: the first written description for each of the patents-in-suit is
`
`at least as early as the earliest priority date of the respective patent-in-suit based
`
`on the earliest filed parent patent application.
`
`Additionally, Alphatec has admitted that NuVasive’s “eXtreme Lateral
`
`Interbody Fusion” product (or “XLIF”), which includes the MaXcess access
`
`system and CoRoent XL implants, embodies the asserted claims of the patents-in-
`
`suit. Doc. No. 48 at 16. Based on information available to NuVasive at this time,
`
`NuVasive states that it launched aspects of XLIF in October 2003 at the North
`
`American Spine Society (NASS) Annual Meeting, including its MaXcess access
`
`system, and specifically MaXcess I. Persons involved in this this launch include
`
`NUVASIVE’S SUPPL OBJ.
`& RESPONSES TO DEFS’
`1ST SET OF ROGS
`
`
`
`21
`
`18-cv-00347-CAB-MDD
`
`EXHIBIT K
`PAGE 7
`
`

`

`Case 3:18-cv-00347-CAB-MDD Document 301-4 Filed 01/15/21 PageID.27261 Page 5 of 13
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`25
`
`26
`
`27
`
`28
`
`
`
`
`
`
`Pat Miles, Eric Finley, and Scot Martinelli. In addition, MaXcess III launched on
`
`September 12, 2006, and MaXcess III Solid launched on November 13, 2008.
`
`In October 2004, at NASS, NuVasive launched the CoRoent XL implant
`
`as part of XLIF. The persons involved in the launch of CoRoent XL are Matthew
`
`Curran, Matthew Copp, Scot Martinelli, Patrick Miles, and David Ivanko.
`
`In addition, pursuant to Local Patent Rule 3.2(b) and Fed. R. Civ. P. 33(d),
`
`NuVasive further states that it will produce and has produced non-privileged
`
`documents from which the information requested can be ascertained, including
`
`documents bearing the following Bates numbers:
`
`NUVA_ATEC0000001 – NUVA_ATEC0000290;
`
`NUVA_ATEC0000544 – NUVA_ATEC0014446;
`
`NUVA_ATEC0014504 – NUVA_ATEC0015487;
`
`NUVA_ATEC0016164 – NUVA_ATEC0016948;
`
`NUVA_ATEC0016949 – NUVA_ATEC0039458;
`
`NUVA_ATEC0039459 – NUVA_ATEC0040421;
`
`Discovery is ongoing and NuVasive reserves its right to amend or
`
`supplement its response to this interrogatory.
`
`SUPPLEMENTAL RESPONSE TO INTERROGATORY NO. 3:
`
`In addition to its previously asserted General and Specific Objections,
`
`NuVasive continues to object that this interrogatory is overly broad, unduly
`
`burdensome, and not proportional to the needs of the case because it seeks a
`
`“detailed” description of information spanning nearly two decades that is no longer
`
`readily accessible to NuVasive due to the passage of time and relevant personnel
`
`departing the company over the intervening 15-plus years. In light of this,
`
`NuVasive maintains that its previous response and citation to documents pursuant
`
`to Fed. R. Civ. P. 33(d) is proper at least because the burden of deriving the
`
`NUVASIVE’S SUPPL OBJ.
`& RESPONSES TO DEFS’
`1ST SET OF ROGS
`
`
`
`22
`
`18-cv-00347-CAB-MDD
`
`EXHIBIT K
`PAGE 8
`
`

`

`Case 3:18-cv-00347-CAB-MDD Document 301-4 Filed 01/15/21 PageID.27262 Page 6 of 13
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`25
`
`26
`
`27
`
`28
`
`
`
`
`
`requested information would be substantially the same for either NuVasive or
`
`Alphatec.
`
`Subject to and without waiving the foregoing objections, NuVasive further
`
`states: Based on a reasonable investigation of information from the personal
`
`knowledge of those relevant persons still at or employed by NuVasive to date,
`
`NuVasive has not identified a disclosure earlier than those provided in its prior
`
`response. Additional persons who may have knowledge regarding the 2004
`
`launch and the earliest use and sale of the embodying CoRoent XL implant,
`
`include Ryan Donahoe.
`
`In addition, pursuant to Fed. R. Civ. P. 33(d), NuVasive has produced and
`
`will produce non-privileged documents from which the information regarding
`
`the launches, and earliest disclosure, use, and sale of the inventions of the
`
`asserted claims of the patents-in-suit, can be ascertained, including documents
`
`bearing the following Bates numbers:
`
` NUVA_ATEC0115139 – NUVA_ATEC0115153;
`
` NUVA_ATEC0040546 – NUVA_ATEC0040573;
`
` NUVA_ATEC0000001 – NUVA_ATEC0000290,
`
`NUVA_ATEC0014504 – NUVA_ATEC0015487,
`
`NUVA_ATEC0016164 – NUVA_ATEC0016948;
`
` NUVA_ATEC0016949 – NUVA_ATEC0039458,
`
`NUVA_ATEC0039459 – NUVA_ATEC0040421.
`
`Finally, NuVasive’s Design History Files (“DHF”) for the various versions
`
`of the embodying components of XLIF (including the MaXcess I access system
`
`and CoRoent XL implant) contain NuVasive’s contemporaneous business records
`
`and documentation regarding, inter alia, the launch of such components, and
`
`include detailed information responsive to this interrogatory. The specific DHF
`
`NUVASIVE’S SUPPL OBJ.
`& RESPONSES TO DEFS’
`1ST SET OF ROGS
`
`
`
`23
`
`18-cv-00347-CAB-MDD
`
`EXHIBIT K
`PAGE 9
`
`

`

`Case 3:18-cv-00347-CAB-MDD Document 301-4 Filed 01/15/21 PageID.27263 Page 7 of 13
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`25
`
`26
`
`27
`
`28
`
`
`
`
`
`documents produced as kept in NuVasive’s ordinary course of business and cited
`
`above are:
`
` DHF-01-002 (re dilators): NUVA_ATEC0000544 –
`
`NUVA_ATEC0009120, NUVA_ATEC0012840 –
`
`NUVA_ATEC0012926;
`
` DHF-02-006 (re access system): NUVA_ATEC0009121 –
`
`NUVA_ATEC0009814, NUVA_ATEC0012463 –
`
`NUVA_ATEC0012465, NUVA_ATEC0012618 –
`
`NUVA_ATEC0012620;
`
` DHF-03-003 (re implants): NUVA_ATEC0009815 –
`
`NUVA_ATEC0010067, NUVA_ATEC0012542 –
`
`NUVA_ATEC0012597;
`
` DHF-04-002 (re dilators); NUVA_ATEC0010068 –
`
`NUVA_ATEC0010509;
`
` DHF-04-004 (re light cables): NUVA_ATEC0010510 –
`
`NUVA_ATEC0011052, NUVA_ATEC0012430 –
`
`NUVA_ATEC0012462;
`
` DHF-06-008 (re shims and XLIF kit components):
`
`NUVA_ATEC0011053 – NUVA_ATEC0012429,
`
`NUVA_ATEC0012466 – NUVA_ATEC0012541,
`
`NUVA_ATEC0012598 – NUVA_ATEC0012617,
`
`NUVA_ATEC0012621 – NUVA_ATEC0012839,
`
`NUVA_ATEC0012936 – NUVA_ATEC0012952;
`
` DHF-06-018 (re dilators): NUVA_ATEC0014000 –
`
`NUVA_ATEC0014446;
`
` DHF-08-012 (re shims and XLIF kit components):
`
`NUVA_ATEC13829 – NUVA_ATEC0013999;
`
`NUVASIVE’S SUPPL OBJ.
`& RESPONSES TO DEFS’
`1ST SET OF ROGS
`
`
`
`24
`
`18-cv-00347-CAB-MDD
`
`EXHIBIT K
`PAGE 10
`
`

`

`Case 3:18-cv-00347-CAB-MDD Document 301-4 Filed 01/15/21 PageID.27264 Page 8 of 13
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`25
`
`26
`
`27
`
`28
`
`
`
`
`
`
` DHF-09-020 (re access system): NUVA_ATEC0012953 –
`
`NUVA_ATEC0013828;
`
` DHF-14-020 (re dilators): NUVA_ATEC0012927 –
`
`NUVA_ATEC0012935.
`
`Discovery is ongoing and NuVasive reserves its right to amend or
`
`supplement its response to this interrogatory.
`
`INTERROGATORY NO. 4:
`
`For each of the patents-in-suit, provide all facts and identify all
`
`corroborating documents regarding the ownership of any right, title, or interest in
`
`or to each patent, including identifying the entity that currently owns the right,
`
`title, or interest; a full explanation of the chain of title to any and all rights, title, or
`
`interests in or to each patent; and the circumstances regarding each entity’s
`
`assignment/acquisition of any right, title, or interest in each of the patents-in-suit
`
`(including, without limitation, the reasons for assignment; dates of acquisition;
`
`valuation of the patents-in-suit; and identification of all individuals knowledgeable
`
`regarding the assignment and/or involved in a negotiation of the assignment, the
`
`persons most knowledgeable regarding the assignment and/or negotiation of the
`
`assignment, and all documents and communications related to such assignment
`
`and/or negotiation of the assignment).
`
`RESPONSE TO INTERROGATORY NO. 4:
`
`NuVasive incorporates by reference each of the General Objections.
`
`NuVasive objects to this interrogatory on the grounds that it contains at least two
`
`discrete subparts, is compound, and constitutes at least two interrogatories. For
`
`example, information regarding any “valuation(s) of the patents-in-suit” is
`
`completely unrelated to information regarding “ownership of any right title, or
`
`interest” in the patents-in-suit. NuVasive objects to this interrogatory as vague and
`
`ambiguous with respect to the term “any right, title, or interest.” NuVasive objects
`
`NUVASIVE’S SUPPL OBJ.
`& RESPONSES TO DEFS’
`1ST SET OF ROGS
`
`
`
`25
`
`18-cv-00347-CAB-MDD
`
`EXHIBIT K
`PAGE 11
`
`

`

`Case 3:18-cv-00347-CAB-MDD Document 301-4 Filed 01/15/21 PageID.27265 Page 9 of 13
`
`
`
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`In addition, NuVasive states that it further intends to rely upon facts set forth
`
`in the Link Declaration (Doc. No. 37-13) at ¶¶ 6-20, 27-35, 38-39, and the Reply
`
`Link Declaration (Doc. No. 77-52) at ¶ 57 FN 12 and 14, along with the exhibits
`
`cited therein, to support its claim that secondary considerations or objective indicia
`
`support the non-obviousness of the asserted claims of the patents-in-suit.
`
`NuVasive also intends to rely on at least the following additional documents to
`
`support its contentions regarding secondary considerations or objective indicia of
`
`non-obviousness:
`
`NUVA_ATEC0119265 – NUVA_ATEC0119267.
`
`Discovery is ongoing and NuVasive reserves its right to amend or
`
`supplement its response to this interrogatory.
`
`12
`
`INTERROGATORY NO. 7:
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`25
`
`26
`
`27
`
`28
`
`
`
`For each of NuVasive’s actual and prospective customers (including, but
`
`not limited to, surgeons, hospitals, and medical groups) for any embodying
`
`products, identify the following:
`
` the surgeon and his or her affiliation, hospital, or medical group;
`
` dates of first and most recent offers for sale;
`
` products and services offered in connection with the first and most
`
`recent offers for sale;
`
` prices of products offered in connection with the first and most recent
`
`offers for sale;
`
` all individuals involved in making the first and most recent offers for
`
`sale;
`
` dates of first and most recent sales;
`
` dates of first and most recent surgeries;
`
` products and services sold in connection with the first and most
`
`recent sales;
`
`NUVASIVE’S SUPPL OBJ.
`& RESPONSES TO DEFS’
`1ST SET OF ROGS
`
`
`
`42
`
`18-cv-00347-CAB-MDD
`
`EXHIBIT K
`PAGE 12
`
`

`

`Case 3:18-cv-00347-CAB-MDD Document 301-4 Filed 01/15/21 PageID.27266 Page 10 of
`13
`
`
`
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`25
`
`26
`
`27
`
`28
`
`
`
` products and services used in the surgeries for the first and most
`
`recent sales;
`
` prices of products sold in connection with the first and most recent
`
`sales;
`
` all individuals involved in making the first and most recent sales; and
`
` the persons most knowledgeable regarding the first and most recent
`
`sales.
`
`RESPONSE TO INTERROGATORY NO. 11:
`
`NuVasive incorporates by reference each of the General Objections.
`
`NuVasive objects to this interrogatory on the grounds that it contains at least three
`
`discrete subparts, is compound, and constitutes at least three interrogatories.
`
`NuVasive objects to this interrogatory as vague and ambiguous with respect to the
`
`term “involved.” NuVasive objects to this interrogatory on the grounds and to the
`
`extent it is overly broad, unduly burdensome, not proportional to the needs of the
`
`case, and not relevant to any claim or defense in this case. Specifically, NuVasive
`
`objects to the interrogatory to the extent it calls for NuVasive to identify
`
`information regarding NuVasive’s prospective customers, identify “all individuals
`
`involved in making the first and most recent offers for sale,” and identify “all
`
`individuals involved in making the first and most recent sales.” NuVasive objects
`
`to this interrogatory to the extent it seeks information outside of NuVasive’s
`
`possession, custody, or control. NuVasive objects to this interrogatory to the extent
`
`it seeks “Privileged Information.”
`
`Subject to and without waiving the foregoing objections, NuVasive responds
`
`as follows: NuVasive does not track some of the specific information requested,
`
`such as all NuVasive personnel that may be “involved” in sales, and/or for all time
`
`periods requested. Subject to these limitations and pursuant to Fed. R. Civ. P.
`
`33(d), NuVasive will identify summary documents containing information it
`
`NUVASIVE’S SUPPL OBJ.
`& RESPONSES TO DEFS’
`1ST SET OF ROGS
`
`
`
`43
`
`18-cv-00347-CAB-MDD
`
`EXHIBIT K
`PAGE 13
`
`

`

`Case 3:18-cv-00347-CAB-MDD Document 301-4 Filed 01/15/21 PageID.27267 Page 11 of
`13
`
`
`
`maintains in the ordinary course of its business from which information relevant to
`
`this interrogatory may be derived.
`
`Discovery is ongoing and NuVasive reserves its right to supplement its
`
`response to this interrogatory.
`
`SUPPLEMENTAL RESPONSE TO INTERROGATORY NO. 11:
`
`Subject to and without waiving the foregoing objections, pursuant to Fed. R.
`
`Civ. P. 33(d), NuVasive further states that it will produce and has produced non-
`
`privileged documents from which the information requested can be ascertained,
`
`including documents bearing the following Bates numbers:
`
`NUVA_ATEC0115139 – NUVA_ATEC0115153;
`
`NUVA_ATEC0119265 – NUVA_ATEC0119266.
`
`Discovery is ongoing and NuVasive reserves its right to amend or
`
`supplement its response to this interrogatory.
`
`
`
`
`
`NUVASIVE’S SUPPL OBJ.
`& RESPONSES TO DEFS’
`1ST SET OF ROGS
`
`
`
`44
`
`18-cv-00347-CAB-MDD
`
`15
`
`
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`25
`
`26
`
`27
`
`28
`
`
`
`EXHIBIT K
`PAGE 14
`
`

`

`Case 3:18-cv-00347-CAB-MDD Document 301-4 Filed 01/15/21 PageID.27268 Page 12 of
`13
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`25
`
`26
`
`27
`
`28
`
`
`
`
`
`
`
`
`Dated: October 22, 2018 WILSON SONSINI GOODRICH & ROSATI,
`P.C.
`
`
`
`By: /s/ Christina Dashe
`
`Paul D. Tripodi II (SBN162380)
`ptripodi@wsgr.com
`Grace J. Pak (SBN 277705)
`gpak@wsgr.com
`633 West Fifth Street, Suite 1550
`Los Angeles, CA 90071
`Telephone: 323-210-2900
`Fax: 866-974-7329
`
`
`
`
`
`Natalie J. Morgan (SBN 211143)
`nmorgan@wsgr.com
`Christina Dashe (SBN 292360)
`cdashe@wsgr.com
`12235 El Camino Real
`San Diego, CA 92130
`Telephone: 858-350-2300
`Fax: 858-350-2399
`
`Wendy L. Devine (SBN 246337)
`wdevine@wsgr.com
`One Market Plaza,
`Spear Tower, Suite 3300
`San Francisco, CA 94105-1126
`Telephone: 415-947-2000
`Fax: 415-947-2099
`
`Sara L. Tolbert (SBN 300945)
`stolbert@wsgr.com
`650 Page Mill Road
`Palo Alto, CA 94304
`Telephone: 650-493-9300
`Fax: 650-493-6811
`
`NUVASIVE’S SUPPL OBJ.
`& RESPONSES TO DEFS’
`1ST SET OF ROGS
`
`45
`
`18-cv-00347-CAB-MDD
`
`
`
`
`
`
`
`EXHIBIT K
`PAGE 15
`
`

`

`Case 3:18-cv-00347-CAB-MDD Document 301-4 Filed 01/15/21 PageID.27269 Page 13 of
`13
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`25
`
`26
`
`27
`
`28
`
`
`
`
`
`
`CERTIFICATE OF SERVICE
`
`The undersigned certifies that a true and correct copy of the foregoing
`
`document has been served on this date to all current and/or opposing counsel of
`
`record, if any to date, who are deemed to have consented to electronic service via
`
`the Court’s CM/ECF system per Civ.L.R. 5.4(d). Any other counsel of record will
`
`be served by electronic mail, facsimile and/or overnight delivery.
`
`I declare under penalty of perjury under the Laws of the United States of
`
`America that the above is true and correct. Executed this 22nd day of October,
`
`2018, at San Diego, California.
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`By: /s/ Christina Dashe
`Christina Dashe
`
`
`
`
`CERTIFICATE OF
`SERVICE
`
`
`1
`
`18-cv-00347-CAB-MDD
`
`EXHIBIT K
`PAGE 16
`
`